OneMedNet (ONMD) has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its quarterly reports for Q1, Q2, and Q3 2024. During H2 2024, the company executed several strategic initiatives including: appointing Bob Golden as interim CFO, hiring key commercial positions, signing an agreement with Bayer’s AI Innovation Platform, enhancing data services with AI, refreshing the Board of Directors, and improving liquidity through $6.4M in private placements. The company also implemented a Bitcoin treasury management strategy and enhanced its OMNi indexer technology for improved data searching capabilities.
OneMedNet (ONMD) ha ripristinato la conformità con la Nasdaq Listing Rule 5250(c)(1) dopo aver presentato i suoi rapporti trimestrali per il primo, secondo e terzo trimestre del 2024. Durante il secondo semestre del 2024, l’azienda ha attuato diverse iniziative strategiche tra cui: la nomina di Bob Golden come CFO ad interim, l’assunzione di figure commerciali chiave, la firma di un accordo con la Piattaforma di Innovazione AI di Bayer, il potenziamento dei servizi di dati con l’IA, il rinnovo del Consiglio di Amministrazione e il miglioramento della liquidità attraverso 6,4 milioni di dollari in collocamenti privati. L’azienda ha inoltre implementato una strategia di gestione del tesoro in Bitcoin e migliorato la tecnologia dell’indice OMNi per ottimizzare le capacità di ricerca dei dati.
OneMedNet (ONMD) ha recuperado el cumplimiento con la regla de cotización 5250(c)(1) de Nasdaq tras presentar sus informes trimestrales de Q1, Q2 y Q3 de 2024. Durante el segundo semestre de 2024, la empresa llevó a cabo varias iniciativas estratégicas, incluyendo: la designación de Bob Golden como CFO interino, la contratación de posiciones comerciales clave, la firma de un acuerdo con la Plataforma de Innovación AI de Bayer, la mejora de los servicios de datos con IA, la renovación de la Junta Directiva y la mejora de la liquidez mediante 6,4 millones de dólares en colocaciones privadas. La empresa también implementó una estrategia de gestión de tesorería en Bitcoin y mejoró su tecnología de indexador OMNi para optimizar las capacidades de búsqueda de datos.
OneMedNet (ONMD)는 2024년 1분기, 2분기 및 3분기에 대한 분기 보고서를 제출한 후 Nasdaq 상장 규칙 5250(c)(1)의 준수를 회복했습니다. 2024년 하반기 동안 회사는 몇 가지 전략적 이니셔티브를 실행했습니다. 여기에는 Bob Golden을 임시 CFO로 임명하고, 핵심 상업 직책을 채용하고, Bayer의 AI 혁신 플랫폼과 계약을 체결하고, AI로 데이터 서비스를 향상시키고, 이사회를 새로 구성하고, 640만 달러의 사모 펀드를 통해 유동성을 개선하는 것이 포함됩니다. 이 회사는 또한 비트코인 재무 관리 전략을 구현하고 데이터 검색 능력을 향상시키기 위해 OMNi 인덱서 기술을 개선했습니다.
OneMedNet (ONMD) a retrouvé sa conformité avec la règle de cotation 5250(c)(1) de Nasdaq après avoir déposé ses rapports trimestriels pour le premier, le deuxième et le troisième trimestre de 2024. Au cours du second semestre 2024, l’entreprise a exécuté plusieurs initiatives stratégiques, y compris : la nomination de Bob Golden en tant que CFO par intérim, le recrutement de postes commerciaux clés, la signature d’un accord avec la plateforme d’innovation IA de Bayer, l’amélioration des services de données avec l’IA, le renouvellement du conseil d’administration et l’amélioration de la liquidité grâce à 6,4 millions de dollars en placements privés. L’entreprise a également mis en œuvre une stratégie de gestion de trésorerie Bitcoin et amélioré sa technologie d’indexeur OMNi pour de meilleures capacités de recherche de données.
OneMedNet (ONMD) hat die Einhaltung der Nasdaq-Listing-Regel 5250(c)(1) wiederhergestellt, nachdem es seine Quartalsberichte für das 1., 2. und 3. Quartal 2024 eingereicht hat. Im zweiten Halbjahr 2024 führte das Unternehmen mehrere strategische Initiativen durch, darunter: die Ernennung von Bob Golden zum Interim CFO, die Einstellung wichtiger Handelspositionen, den Abschluss einer Vereinbarung mit der AI Innovationsplattform von Bayer, die Verbesserung der Datendienste mit KI, die Auffrischung des Vorstands und die Verbesserung der Liquidität durch 6,4 Millionen USD in privaten Platzierungen. Das Unternehmen implementierte auch eine Bitcoin-Treasury-Management-Strategie und verbesserte seine OMNi-Indexer-Technologie für verbesserte Datenabrufmöglichkeiten.
Positive
- Regained Nasdaq listing compliance
- Secured $6.4M through private placements
- Signed agreement with Bayer’s AI Innovation Platform
- Strengthened management team with key hires
- Enhanced data services with AI technology implementation
Negative
- Required interim CFO appointment indicates financial management challenges
- Needed multiple quarters to achieve reporting compliance
Insights
The compliance regaining with NASDAQ listing requirements represents a critical milestone for OneMedNet, particularly given its micro-cap status with a market cap of
The
Key operational developments include the appointment of seasoned executives and the enhancement of their data services through AI integration. The partnership with Bayer’s AI Innovation Platform could potentially accelerate revenue growth in the imaging Real World Data market, which is experiencing rapid expansion due to increasing demand for real-world evidence in drug development and clinical research.
However, investors should note that multiple delayed filings often indicate underlying internal control weaknesses. While these issues appear to be addressed through new management appointments and process improvements, careful monitoring of future filing compliance will be crucial.
The integration of Generative AI into OneMedNet’s data de-identification and curation services, coupled with the deployment of their OMNi 2.0 indexer, represents a significant technological advancement. This upgrade should substantially improve the efficiency and accuracy of medical imaging data processing, a important factor in the competitive Real World Data market.
The strategic partnership with Bayer’s AIIP is particularly noteworthy as it validates OneMedNet’s technological capabilities and could accelerate the development of AI-driven solutions in medical imaging analysis. The combination of enhanced data processing capabilities and established partnerships positions OneMedNet to capitalize on the growing demand for high-quality imaging real-world data in pharmaceutical research and development.
MINNEAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (“iRWD™”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) based on the filing of its periodic reports on Form 10-Q for the fiscal quarters ended March 31, June 30 and September 30, 2024. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming compliance with the Rule.
Aaron Green, Chief Executive Officer, stated, “We are pleased to have filed our financial results for the first three quarters of 2024. Together with the recently completed reaudit of our 2023 financial statements, we are now current on our periodic financial reporting and can focus on growing our business going forward.”
During the second half of 2024, we developed and started to execute on our strategic plan by:
- Appointing Bob Golden as Chief Financial Officer, on a interim basis to oversee enhancements in the Company’s financial reporting processes.
- Hiring a Director of Business Development, Margaret Nash, and Vice President of Marketing, Michael Wong, to continue to build our commercial presence with Life Science organizations, additionally recently signing an agreement with Bayer’s AI Innovation Platform (AIIP) announced in early December.
- Enhancing our Data De-Identification and curation service leveraging Generative AI and deploying OneMedNet’s 2.0 generation indexer OMNi, to improve the speed and accuracy of data searching and indexing.
- Refreshing the composition of the Company’s Board of Directors with three new directors who have relevant industry, financial and public company expertise.
- Improving liquidity by raising approximately
$6.4M in private placements with Off the Chain Capital and an affiliate of Discovery Capital Management. - Enhancing treasury management with a Bitcoin on the balance sheet strategy.
OneMedNet is now in a position to take advantage of the growing Real World Data market with a meaningful market share.
About OneMedNet Corporation
OneMedNet provides innovative solutions that unlock the significant value contained within the Real-World Data (“RWD”) repositories of over 1,400 healthcare system and provider sites that currently comprise its iRWD™ network. OneMedNet’s proprietary iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records, ECGs, EEGs, prescriptions, physician notes, laboratory results, and uniquely, medical imaging. Employing its robust iRWD™ platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.
OneMedNet’s platform is designed to address diverse clinical requirements across various domains, such as rare diseases, central nervous system disorders, oncology, cardiology and women’s health. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet’s strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timeline for the Company to regain compliance with the listing rules of The Nasdaq Stock Market LLC relating to maintaining a minimum bid price of
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
SOURCE: ONEMEDNET CORPORATION
FAQ
How much funding did OneMedNet (ONMD) raise in private placements in 2024?
OneMedNet raised approximately $6.4M in private placements with Off the Chain Capital and an affiliate of Discovery Capital Management.
What strategic partnership did ONMD announce in December 2024?
OneMedNet announced a partnership agreement with Bayer’s AI Innovation Platform (AIIP) in early December 2024.
What technology improvements did ONMD implement in 2024?
OneMedNet enhanced its Data De-Identification and curation service with Generative AI and deployed the 2.0 generation indexer OMNi for improved data searching and indexing.
How did OneMedNet (ONMD) resolve its Nasdaq compliance issues?
OneMedNet regained compliance by filing its Form 10-Q reports for Q1, Q2, and Q3 2024, along with completing a reaudit of 2023 financial statements.